.png)
SummaryA managed entry agreement is what happens when a payer wants a medicine available and cannot accept its list price, or cannot yet judge its value. Instead of refusing, the two sides agree a mechanism: a discount, a payback, a volume cap, or a payment linked to outcomes. The agreement is usually confidential, which is why these instruments shape European prices heavily and appear in published data not at all.
Financial agreements change what is paid, without reference to how the product performs. Discounts, price volume agreements, paybacks, budget caps and free stock arrangements belong here.
Performance based agreements link payment to what happens in practice: continued payment only for responders, a refund where a defined outcome is not reached, or staged payments over time.
The second family attracts most of the attention in the literature. The first family dominates practice. In a comparative analysis of managed entry agreements across 13 European countries covering 2016 to 2022, confidential discounts were by far the most common instrument at 495 of the recorded agreements, roughly 73 percent, followed by paybacks at 92, about 14 percent, and price volume agreements at 37. The study is published in The European Journal of Health Economics.
That distribution matters for anyone modelling European prices. The dominant mechanism is a straightforward confidential discount, not an elaborate outcome scheme.
| Instrument | What it changes | Visible in public data |
|---|---|---|
| Confidential discount | The price actually paid | Rarely, and then only as an existence |
| Payback | A retrospective payment to the payer | Sometimes at sector level |
| Price volume agreement | The price above a defined volume | Existence sometimes, terms rarely |
| Budget cap | Total exposure for the payer | Existence sometimes |
| Outcome based payment | Payment tied to a defined clinical result | Existence sometimes, amounts almost never |
The column on the right is the reason this subject is difficult. For most of these instruments the only publicly knowable fact is that one exists, and even that is not consistently recorded.
They are administratively expensive. An outcome based agreement needs a defined outcome, a way to measure it per patient, an agreed data source, a reconciliation process and a dispute mechanism. Each of those is a system that somebody has to build and run.
A confidential discount needs none of that. It is a number in a contract.
That asymmetry explains the distribution in the data far better than any argument about which instrument is conceptually superior. Where registries and routine data are strong, outcome based schemes are more feasible. Where they are not, the discount wins by default.
Three pressures produce them.
Uncertainty about value. A new medicine may show benefit in a trial population that does not obviously match the population that will receive it. An agreement lets treatment start while evidence accumulates.
Budget predictability. A payer facing an unpredictable number of eligible patients can cap exposure without capping access.
Price levels that cannot be published. A payer needs a lower effective price. A manufacturer cannot lower the list price without that reduction travelling into other countries through their reference baskets. A confidential agreement resolves the tension by separating the published price from the paid one.
The third reason is the one that connects managed entry agreements directly to everything else in European pricing. External reference pricing reads published prices. Confidentiality exists in large part because those published prices are read abroad.
Confidentiality has real costs, and they are documented rather than speculative.
A survey among European pricing and reimbursement authorities, published in Health Policy, examined medicine price transparency and confidential managed entry agreements and found that confidential agreements complicate international price comparison and undermine the informational basis on which authorities work. The same theme appears in the more recent comparative analysis: incomplete and non standardised reporting limits the ability to assess financial performance and to compare across countries.
The constructive proposal in that literature is worth repeating, because it is not a demand to publish contracts. Harmonised, aggregated reporting would improve the evidence base for pharmaceutical policy evaluation without breaching product specific confidentiality. In other words, the objection is to the absence of any aggregate picture, not to commercial confidentiality as such.
Four rules follow, and they apply to any commercial or internal dataset.
No published European dataset contains paid prices. The shared database of national pricing authorities had not implemented actually paid prices as of 2022. If a vendor offers net prices, ask where they come from, what they cover and how old they are.
A list price comparison is still legitimate, provided it is labelled as such. It describes the regulated or notified level, which is the level that reference systems read and that reimbursement rules attach to.
Mechanisms can be named even where amounts cannot. In several countries the existence of an agreement is public while the amount is not, and statutory rebate rates are public even where the resulting net price per pack is not. Naming the mechanisms that are known to reduce a figure is more honest than silence and more defensible than an invented number.
A modelled net price is acceptable only as a model. Start from the published list price at a stated level and date, apply statutory reductions whose rates are public and name their legal basis, add a negotiated component only where a document exists, and weight by volume where volume data exists. Every step then remains auditable.
Germany is instructive because two layers sit on top of each other. The outcome of the central negotiation after the benefit assessment becomes part of the published price, so a negotiated figure is visible, which is rare in Europe. Underneath it, rebate contracts between individual sickness funds and manufacturers are not public.
A team used to German data therefore tends to assume that negotiated prices are generally visible in Europe. They are not, and Germany itself is only partly transparent: the visible negotiated amount is not the end of the chain.
Market access and pricing teams. The published price of a comparator is not what the payer pays for it. A value argument built on published comparator prices overstates the competitive gap in markets with heavy rebating, and the effect is strongest in segments with intense generic or biosimilar competition.
Hospital pharmacy and procurement. The published pharmacy purchase price is the ceiling of a negotiation, not its outcome. Tender prices are the operative figure and are usually confidential, so a published price serves as a plausibility check and as a fallback where no tender exists.
Payers and analysts. Cross-country comparisons at list level measure regulatory outcomes. That is a legitimate object of study, as long as the conclusion drawn is about regulation rather than about expenditure.
Where did the figure come from? A contract, a tender award, a survey or a model. Each carries a different reliability and a different legal basis for reuse.
What does it cover? Net data, where it exists at all, usually covers a narrow segment such as hospital tenders in one country rather than a national universe.
How old is it? Tender awards are point in time. A price from a two year old award says little about today's contract.
Managed entry agreements are the mechanism through which European payers buy access at a price they can defend and manufacturers protect a list price that other countries read. They are dominated by confidential discounts rather than by outcome schemes, they are largely invisible in published data, and their invisibility is a direct consequence of the reference pricing systems described elsewhere in this cluster. A price analysis that acknowledges them, names the mechanisms it cannot quantify and labels its own level remains defensible. One that quietly treats a published price as a paid price does not.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus external reference pricing in Europe and list price vs net price.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
